title: Current Development of Anti-Cancer Drug S-1.
abstract: S-1 is a novel oral fluoropyrimidine derivative, widely used for treating gastric, pancreatic, lung, head, neck and breast carcinomas. It is designed to enhance the clinical utility of an oral fluoropyrimidine and is associated with low gastrointestinal toxicity. S-1 consists of three pharmacological agents (at a molar ratio of 1:0.4:1)-Tegafur (FT), a prodrug of 5-Fluorouracil (5-FU), 5-Chloro-2-4-Dihydroxypyridine (CDHP), which inhibits the activity of Dihydropyrimidine Dehydrogenase (DPD) and Oxonic Acid (Oxo), which reduces Gastrointestinal (GI) toxicity of 5-FU. The present article reviews the current development of clinical study of S-1.
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: Pratima
authors.initials: P
authors.lastname: Chhetri
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: Anil
authors.initials: A
authors.lastname: Giri
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: Suraj
authors.initials: S
authors.lastname: Shakya
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: Sujana
authors.initials: S
authors.lastname: Shakya
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: Binaya
authors.initials: B
authors.lastname: Sapkota
authors.affiliation: Lecturer, Department of Pharmaceutical Sciences, Faculty of Health Science, Nobel College , Kathmandu, Nepal .
authors.forename: K C
authors.initials: KC
authors.lastname: Pramod
keywords: Cisplatin; Irinotecan; Paclitaxel; Pharmacokinetics